spacer
The Healthcare Sales & Marketing Network celebrates 28 years serving the medical sales & marketing community.Connecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product LinesConnecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product Lines

Searching News Database:  melanocortin 

 HSMN NewsFeed - 28 Jun 2021
Palatin Announces New Additions to Its Senior Leadership Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 6 Jun 2019
Palatin Technologies Granted FDA Orphan Drug Designation -- PL-8177 for the Treatment of Non-Infectious Uveitis
Biopharmaceuticals Ophthalmology FDA
 HSMN NewsFeed - 1 Aug 2017
Rhythm Expands Executive Leadership Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 11 May 2017
Rhythm Receives Expanded FDA Breakthrough Therapy Designation for Setmelanotide for Rare Genetic Disorders of Obesity
Biopharmaceuticals FDA
 HSMN NewsFeed - 3 Feb 2017
Palatin Technologies Announces Closing of License Agreement with AMAG Pharmaceuticals for North American Rights to Rekynda(TM)
Biopharmaceuticals Licensing Distribution
 HSMN NewsFeed - 25 Aug 2016
Mallinckrodt Receives FDA Fast-Track Designation for Synacthen(R) Depot IND Application
Biopharmaceuticals FDA
 HSMN NewsFeed - 5 Jan 2016
Rhythm and Camurus Announce License Agreement for Extended Release FluidCrystal Setmelanotide
Biopharmaceuticals Drug Delivery Licensing
 HSMN NewsFeed - 16 Dec 2015
Rhythm Appoints David Meeker, MD, and David McGirr to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 11 Jun 2013
Questcor Pharmaceuticals Acquires Rights to Synacthen(R)
Biopharmaceuticals Acquisitions
 HSMN NewsFeed - 27 Nov 2012
Rhythm Expands Series B Financing to $33 Million; Adds Pfizer Ventures as an Investor
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 13 Jun 2012
Rhythm Raises $25M in Series B Financing for Diabetes and Obesity Therapeutics
Biopharmaceuticals Endocrinology Venture Capital
 HSMN NewsFeed - 16 Nov 2010
Palatin Technologies Appoints Jeffrey D. Edelson, M.D., Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 8 Sep 2010
Rhythm Closes $40 Million Series A Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 30 Aug 2007
King Pharmaceuticals and Palatin Technologies Delay Immediate Plans for Phase 3 Clinical Program With Bremelanotide for Erectile Dysfunction
Biopharmaceuticals
 HSMN NewsFeed - 20 Dec 2006
Palatin Technologies and King Pharmaceuticals Complete Enrollment in Pre-Menopausal Cohort of a Phase 2 Clinical Trial Evaluating Bremelanotide in Pre- and Post-Menopausal Female Sexual Dysfunction Patients
Biopharmaceuticals
 HSMN NewsFeed - 6 Nov 2006
Palatin Technologies and King Pharmaceuticals Report Results For Two Phase 2B Clinical Trials Evaluating Bremelanotide in Male Erectile Dysfunction Patients
Biopharmaceuticals
Return to NewsFeed  

 Additional items found! 19

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 19 additional stories matching:
melanocortin
(Password required)
FindReps - screen and connect with rep candidates anonymously, in real time.

FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.


RepJobs - Job Opportunities for Direct Sales Reps and New Product Lines for Independents!

RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!